HROW vs. CAVA

Last updated Jun 4, 2026

HROW (Harrow Health, Inc.) and CAVA (CAVA Group Inc.) are both stocks. HROW operates in Drug Manufacturers - Specialty & Generic (Healthcare), while CAVA operates in Restaurants (Consumer Cyclical). Over the past year, HROW returned 13.57% vs -12.00% for CAVA. At a 0.25 correlation, their price movements are largely independent.

Performance

HROW vs. CAVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Harrow Health, Inc. (HROW) and CAVA Group Inc. (CAVA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, HROW achieves a -32.00% return, which is significantly lower than CAVA's 21.54% return.

HROW

• 1D: 1.40%
• 1M: -17.11%
• YTD: -32.00%
• 6M: -25.16%
• 1Y: 13.57%
• 3Y*: 19.43%
• 5Y*: 29.87%
• 10Y*: 23.55%

CAVA

• 1D: -1.53%
• 1M: -20.02%
• YTD: 21.54%
• 6M: 30.90%
• 1Y: -12.00%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

HROW vs. CAVA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
HROW Harrow Health, Inc.	-32.00%	46.05%	199.55%	-40.65%
CAVA CAVA Group Inc.	21.54%	-47.97%	162.45%	-1.83%

Correlation

The correlation between HROW and CAVA is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.22
Correlation (All Time) Calculated using the full available price history since Jun 16, 2023	0.25

Fundamentals

EPS HROW : -$0.39 CAVA : $0.54
PS Ratio HROW : 4.70 CAVA : 7.15
Total Revenue (TTM) HROW : $268.68M CAVA : $1.18B
Gross Profit (TTM) HROW : $199.11M CAVA : $216.81M
EBITDA (TTM) HROW : $22.70M CAVA : $150.65M

Return for Risk

HROW vs. CAVA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HROW

HROW Risk / Return Rank: 48
HROW Sharpe Ratio Rank: 48
HROW Sortino Ratio Rank: 47
HROW Omega Ratio Rank: 49
HROW Calmar Ratio Rank: 47
HROW Martin Ratio Rank: 48

CAVA

CAVA Risk / Return Rank: 32
CAVA Sharpe Ratio Rank: 32
CAVA Sortino Ratio Rank: 31
CAVA Omega Ratio Rank: 31
CAVA Calmar Ratio Rank: 33
CAVA Martin Ratio Rank: 32

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HROW vs. CAVA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and CAVA Group Inc. (CAVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HROW	CAVA	Difference
Sharpe ratio Return per unit of total volatility	0.21	-0.21	+0.42
Sortino ratio Return per unit of downside risk	0.72	0.09	+0.64
Omega ratio Gain probability vs. loss probability	1.11	1.01	+0.10
Calmar ratio Return relative to maximum drawdown	0.29	-0.23	+0.52
Martin ratio Return relative to average drawdown	0.66	-0.46	+1.12
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HROW vs. CAVA - Sharpe Ratio Comparison

The current HROW Sharpe Ratio is 0.21, which is higher than the CAVA Sharpe Ratio of -0.21. The chart below compares the historical Sharpe Ratios of HROW and CAVA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	HROW	CAVA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.21	-0.21	+0.42
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.43	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.33	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	0.30	-0.35

Drawdowns

HROW vs. CAVA - Drawdown Comparison

The maximum HROW drawdown since its inception was -99.46%, which is greater than CAVA's maximum drawdown of -71.11%. Use the drawdown chart below to compare losses from any high point for HROW and CAVA.

Drawdown Indicators

	HROW	CAVA	Difference
Max Drawdown Largest peak-to-trough decline	-99.46%	-71.11%	-28.35%
Max Drawdown (1Y) Largest decline over 1 year	-47.03%	-52.65%	+5.62%
Max Drawdown (3Y) Largest decline over 3 years	-63.32%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-71.15%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-71.15%	—	—
Current Drawdown Current decline from peak	-75.86%	-52.72%	-23.14%
Average Drawdown Average peak-to-trough decline	-86.74%	-29.99%	-56.75%
Ulcer Index Depth and duration of drawdowns from previous peaks	20.50%	26.20%	-5.70%

Volatility

HROW vs. CAVA - Volatility Comparison

Harrow Health, Inc. (HROW) has a higher volatility of 29.71% compared to CAVA Group Inc. (CAVA) at 15.29%. This indicates that HROW's price experiences larger fluctuations and is considered to be riskier than CAVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HROW	CAVA	Difference
Volatility (1M) Calculated over the trailing 1-month period	29.71%	15.29%	+14.42%
Volatility (6M) Calculated over the trailing 6-month period	55.43%	41.52%	+13.91%
Volatility (1Y) Calculated over the trailing 1-year period	64.81%	57.28%	+7.53%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	69.96%	59.24%	+10.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.13%	59.24%	+11.89%

Dividends

HROW vs. CAVA - Dividend Comparison

Neither HROW nor CAVA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

HROW vs. CAVA - Profitability Comparison

The chart below illustrates the profitability comparison between Harrow Health, Inc. and CAVA Group Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HROW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harrow Health, Inc. reported a gross profit of 27.05M and revenue of 44.20M. Therefore, the gross margin over that period was 61.2%.

CAVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CAVA Group Inc. reported a gross profit of 40.95M and revenue of 274.99M. Therefore, the gross margin over that period was 14.9%.

HROW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harrow Health, Inc. reported an operating income of -22.08M and revenue of 44.20M, resulting in an operating margin of -50.0%.

CAVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CAVA Group Inc. reported an operating income of 8.43M and revenue of 274.99M, resulting in an operating margin of 3.1%.

HROW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harrow Health, Inc. reported a net income of -27.60M and revenue of 44.20M, resulting in a net margin of -62.4%.

CAVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CAVA Group Inc. reported a net income of 4.92M and revenue of 274.99M, resulting in a net margin of 1.8%.

Frequently Asked Questions

Can I hold both HROW and CAVA in my portfolio?

HROW and CAVA have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, HROW or CAVA?

HROW has higher volatility (29.71%) compared to CAVA (15.29%). In terms of maximum drawdown, HROW dropped -99.46% vs CAVA's -71.11%.

Which has better risk-adjusted returns?

HROW currently has the higher Sharpe Ratio (0.21 vs -0.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.